Adebrelimab for advanced small cell lung cancer in routine care

A Real-world Study on the Efficacy and Safety of Adebrelimab in the Treatment of Advanced-stage Small Cell Lung Cancer

This project will try adebrelimab, a PD-L1 blocker, in adults with extensive-stage small cell lung cancer to see how safe it is and how well it controls the disease in routine clinical care.

Quick facts

• Study type: Observational
• Enrollment: 500 (estimated)
• Ages: 18 Years to 100 Years
• Sex: All
• Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine (other)
• Drugs / interventions: adebrelimab
• Locations: 1 site (Shanghai)
• Trial ID: NCT07434518 on ClinicalTrials.gov

What this trial studies

This observational real-world study follows adults with extensive-stage small cell lung cancer who are eligible for or already receiving adebrelimab, collecting safety and outcome data without altering planned treatment. Safety monitoring focuses on immune-related adverse events, particularly grade ≥3 events, from the first dose until 90 days after the last dose, while efficacy endpoints include overall survival, progression-free survival, objective response rate, and disease control rate. The study will also explore how baseline factors such as brain or liver metastases and biomarker status relate to prognosis. Data are collected at several hospitals in Shanghai as part of routine clinical practice.

Who should consider this trial

Good fit: Adults (≥18) with histologically or cytologically confirmed extensive-stage small cell lung cancer who are judged by their physician to be eligible for or already receiving adebrelimab are ideal candidates.

Not a fit: Patients receiving other immune-modulating therapies, enrolled in other interventional trials, with concurrent other malignancies, or lacking key clinical data are unlikely to participate or benefit from this observational program.

Why it matters

Potential benefit: If successful, the study could confirm adebrelimab's safety and real-world effectiveness and help clinicians use it more confidently for extensive-stage SCLC.

How similar studies have performed: Other PD-1/PD-L1 agents have shown survival benefit when added to chemotherapy in extensive-stage SCLC, so this study builds on class-level successes though adebrelimab-specific real-world evidence remains limited.

Eligibility criteria

Inclusion Criteria:

* Histologically or cytologically confirmed extensive-stage small cell lung cancer;
* Age ≥ 18 years;
* The investigator determines that the patient is eligible for or is already receiving adebrelimab treatment.

Exclusion Criteria:

* Patients concurrently receiving other immune-modulating drugs or therapies;
* Patients currently participating in other interventional studies;
* Patients with concurrent other malignancies;
* Patients with missing key study-related data.

Where this trial is running

Shanghai

• Shanghai General Hospital — Shanghai, China (RECRUITING)

Study contacts

• Study coordinator: Qingnan Zhao, PhD

Conditions: Small Cell Lung Cancer, Safety, efficacy, SCLC